SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) April 22, 1998
SIGA Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware 0-23047 13-864870
(State or other jurisdiction of Commission File Number (I.R.S. Employer
incorporation or organization) Identification Number)
420 Lexington Avenue, Suite 620, New York, NY 10170
(Address of principal executive offices) (zip code)
(212) 672-9100
(Registrant's telephone number including area code)
None
(Former name, former address and former fiscal year,
if changed since last report)
<PAGE>
Item 5 Other Events
On April 22, 1998, SIGA Pharmaceuticals, Inc. ("SIGA") announced a series of key
management changes implemented by SIGA's Board of Directors that began with the
appointment of Walter Flamenbaum, M.D., as President in February 1998.
Flamenbaum is a veteran of Therics, Inc., a Johnson and Johnson funded company.
Joshua Schein, Ph.D., a founder and director of SIGA, has agreed to serve as
interim CEO and Judson Cooper, M.B.A., a founder and director of SIGA, has
agreed to serve as interim Chairman, until a permanent replacement can be found
for David de Weese, who resigned as Chairman and CEO to join an investment
management firm.
SIGA also announced the appointment of Thomas N. Konatich as Vice President,
Finance, and Chief Financial Officer, replacing Dr. Schein.
Mr. Konatich joins SIGA from Innapharma, Inc., a privately held pharmaceutical
development company, where he served as CFO and Director with senior management
responsibilities in areas including accounting, business development, investor
relations, risk management and legal compliance. From 1993-1996 he was Vice
President and CFO of Seragen, Inc., a biopharmaceutical development company.
While at Seragen, he had a key role in the successful completion of several
financings as well as the development of a strategic alliance with a major
pharmaceutical company. Prior to joining Seragen, Mr. Konatich spent over 15
years in key financial positions in the biotechnology and pharmaceutical
industries.
Mr. Konatich received his M.B.A. in Finance from Columbia University Graduate
School of Business in 1968 and earned a B.B.A. degree in Economics at St. John's
University in 1967.
<PAGE>
SIGNATURE PAGE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
SIGA PHARMACEUTICALS, INC.
Date: April 22, 1998 /s/ Joshua Schein, Ph.D.
-------------------------
Joshua Schein, Chief Executive Officer
